肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Nat Genet：与东亚女性乳腺癌有关的3种基因

2014-08-08 佚名 手牵手博客站

乳腺癌东亚女性基因突变
关注

在线发表于《自然-遗传学》上的一项研究报告了影响东亚女性乳腺癌的3种遗传变化。这项研究结果为这类人群的乳腺癌遗传学研究提供了新见解。 大多数乳腺癌研究聚焦的研究对象是具有欧洲血统的女性。来自中日韩等国家组成的大型研究团队研究了超过22000位患有乳腺癌的东亚女性，确定了数个可导致乳腺癌发生的针对亚洲的特定遗传变化。 他们找到靠近3种基因--ARRDC3、 PRC

在线发表于《自然-遗传学》上的一项研究报告了影响东亚女性乳腺癌的3种遗传变化。这项研究结果为这类人群的乳腺癌遗传学研究提供了新见解。

大多数乳腺癌研究聚焦的研究对象是具有欧洲血统的女性。来自中日韩等国家组成的大型研究团队研究了超过22000位患有乳腺癌的东亚女性，确定了数个可导致乳腺癌发生的针对亚洲的特定遗传变化。

他们找到靠近3种基因--ARRDC3、 PRC1和ZC3H11A的DNA序列变化。其中两种序列变化的确认位置在负责调控其他周围基因表达的部分基因组中。

ARRDC3和PRC1突变分别与乳腺癌生长和乳腺癌患者存活率有关联。而ZC3H11A在乳腺癌中的作用仍未知。

原始出处：

Cai Q1, Zhang B1, Sung H2, Low SK3, Kweon SS4, Lu W5, Shi J1, Long J1, Wen W1, Choi JY6, Noh DY7, Shen CY8, Matsuo K9, Teo SH10, Kim MK11, Khoo US12, Iwasaki M13, Hartman M14, Takahashi A3, Ashikawa K15, Matsuda K16, Shin MH17, Park MH18, Zheng Y5, Xiang YB19, Ji BT20, Park SK21, Wu PE22, Hsiung CN22, Ito H23, Kasuga Y24, Kang P25, Mariapun S10, Ahn SH26, Kang HS27, Chan KY28, Man EP12, Iwata H29, Tsugane S30, Miao H31, Liao J32, Nakamura Y33, Kubo M15; DRIVE GAME-ON Consortium, Delahanty RJ1, Zhang Y1, Li B34, Li C35, Gao YT19, Shu XO1, Kang D21, Zheng W1.Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1.Nat Genet. 2014 Aug;46(8):886-90. doi: 10.1038/ng.3041. Epub 2014 Jul 20.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880219, encodeId=a4ce1880219a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 27 02:08:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17093, encodeId=c8711e093b2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:32:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048612, encodeId=ef2f204861267, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 14 10:08:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733707, encodeId=a1541e33707f7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Sep 04 23:08:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685962, encodeId=332f1685962c9, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu May 21 07:08:00 CST 2015, time=2015-05-21, status=1, ipAttribution=)]
    2015-05-27 liye789132251

    #Nat#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1880219, encodeId=a4ce1880219a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 27 02:08:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17093, encodeId=c8711e093b2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:32:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048612, encodeId=ef2f204861267, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 14 10:08:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733707, encodeId=a1541e33707f7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Sep 04 23:08:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685962, encodeId=332f1685962c9, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu May 21 07:08:00 CST 2015, time=2015-05-21, status=1, ipAttribution=)]
    2015-02-27 xiaoai5777

    不错的文章，学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1880219, encodeId=a4ce1880219a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 27 02:08:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17093, encodeId=c8711e093b2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:32:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048612, encodeId=ef2f204861267, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 14 10:08:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733707, encodeId=a1541e33707f7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Sep 04 23:08:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685962, encodeId=332f1685962c9, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu May 21 07:08:00 CST 2015, time=2015-05-21, status=1, ipAttribution=)]
    2015-04-14 cy0324

    #Gene#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1880219, encodeId=a4ce1880219a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 27 02:08:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17093, encodeId=c8711e093b2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:32:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048612, encodeId=ef2f204861267, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 14 10:08:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733707, encodeId=a1541e33707f7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Sep 04 23:08:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685962, encodeId=332f1685962c9, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu May 21 07:08:00 CST 2015, time=2015-05-21, status=1, ipAttribution=)]
    2014-09-04 canlab

    #NET#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880219, encodeId=a4ce1880219a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 27 02:08:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17093, encodeId=c8711e093b2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:32:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048612, encodeId=ef2f204861267, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 14 10:08:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733707, encodeId=a1541e33707f7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Sep 04 23:08:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685962, encodeId=332f1685962c9, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu May 21 07:08:00 CST 2015, time=2015-05-21, status=1, ipAttribution=)]
    2015-05-21 江川靖瑶

    #Genet#

    0

相关资讯

Nat Genet：GWAS研究发现三个东亚的乳腺癌风险位点

美国Vanderbilt University领导的一个国际研究小组对数万名东亚妇女开展了三阶段的全基因组关联研究（GWAS），在1号、5号和15号染色体上找到了3个乳腺癌风险位点。这项成果于7月20日发表在Nature Genetics上。 研究小组最初的工作是鉴定风险位点附近基因和调控区域的相关功能。这些位点不仅适用于评估此群体的乳腺癌风 险，也有助于了解疾病新的生物学特征。文章的资深作者

J Control Release：蜂毒液可能是乳腺癌的潜在药物

近日，Institute for Biomedical Research (IRB Barcelona)科学家利用体外试验发现，用蜂毒液可杀死肿瘤细胞。下一步研究将是测试其在小鼠肿瘤模型中的有效性。实际上蜂毒早被研究用于帕金森，过敏等疾病的治疗（资讯：BMC Complement Altern Med：蜂毒针灸可能用于帕金森病的治疗 ） 。 尽管目前正在开发各种化合物对抗癌症，但它们都具有严重的

索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）

拜耳（Bayer）和安进（Amgen）旗下Onyx制药7月24日公布了有关抗癌药多吉美（Nexavar，通用名：sorafenib，索拉非尼）的一项III期研究(RESILIENCE)的数据。该项研究是一项随机、双盲、安慰剂对照III期研究，在537例既往对紫杉类药物（taxane）有抵抗或治疗失败、同时对蒽环类药物（anthracycline）有抵抗或治疗失败或不适于进一步的蒽环类药物治疗的

Clin Cancer Res：乳腺导管原位癌术前局部应用他莫昔芬凝胶同样有效

Clinical Cancer Research 7月15日在线发表的一项小型phase 2研究显示，与口服他莫昔芬相比，局部使用4-羟基他莫昔芬（4-OHT，他莫昔芬的抗雌激素代谢产物）凝胶制剂在乳腺导管原位癌（DCIS）术前应用，与口服他莫西芬同样有效，支持对这一局部外用治疗进行进一步研究（Clin. Cancer Res. 2014;20:3672-82）。这是一项随机、双盲、

Nat Cell Biol：促进乳腺癌细胞对放射疗法产生耐受的特殊蛋白ZEB1

近日，来自美国德州大学MD安德森癌症中心的研究人员通过研究发现，一种名为ZEB1（锌指E盒结合同源框蛋白）的蛋白质可以促进乳腺癌对放射疗法产生耐受性，研究者Li Ma博士表示，蛋白质ZEB1实际上可以帮助乳腺肿瘤细胞修复因辐射疗法带来的DNA损伤，而实现这一修复的机制或许是通过DNA损伤反应路径，相关研究刊登于国际杂志Nature Cell Biology上。 放射疗法可以通过诱导DNA破

NICE 支持 Intrabeam 放疗用于乳腺癌治疗

英国国家卫生与临床优化研究所(NICE)支持 Intrabeam 单次术中放疗纳入英国国民健康服务体系(NHS)用于乳腺癌患者的治疗。已公布的 NICE 指南(草案)建议，对早期乳腺癌患者应考虑应用 Intrabeam 放疗。作为一次性放疗方案，Intrabeam 术中放疗可减少患者前往医院就诊的次数。 NICE 卫生技术评估中心主任 Carole Longson 教授表示，Intrabeam